Current

CIHR (2020 - 2025)

“Use of antimicrobial peptides, LL-37/17BIPHE2, as vaginal spermicides/microbicides as part of multipurpose prevention technology (MPT)”

Principal Investigators: N. Tanphaichitr, J.B. Angel, S. Gadde, P.M. Sheth

CIHR (2024-2025)

“HIV Vaccines: Search for a Cure”

Principal Investigator: J.B. Angel
Co-Investigator: M.D. Grant

CIHR (2024 - 2029)

“CIHR Pan-Canadian Network for HIV/AIDS and Sexually Transmitted and Blood Borne Infections (STBBI) Clinical Trials Research (CTN)”

Principal Investigators: M.B. Klein, M. Habanyama, E. Mandarino, C. Martin, J.B. Angel, et al.

CIHR (2025 - 2029)

“Canadian HIV Cure Enterprise 3.0: Targeting tissue HIV reservoirs”

Principal Investigators: E.A. Cohen, J.B. Angel, N. Chomont, T.T. Murooka, P. Ancuta, et al.

Select Previously Held

CIHR (2009 - 2014)

"Regulation of IL-12 family of TH1 cytokines IL-12, IL-23 and IL-27 by HIV"

Principal Investigators: J.B. Angel and A. Kumar

CIHR (2012 - 2017)

"Regulation and function of soluble IL-7 receptor alpha (CD127) in HIV infection"

Principal Investigator: J.B. Angel

CIHR (2014 - 2018)

"The Canadian HIV Cure Enterprise (CanCURE)"

Principal Investigators: E. A. Cohen, P. Ancuta, J.B. Angel, J-P Routy, K.R. Fowke et al.

http://www.cancurehiv.org/

CIHR (2014 - 2018)

"Antimicrobial host defense peptides: their potential use as vaginal contraceptives with anti-HIV properties"

Principal Investigators: N. Tanphaichitr and J.B. Angel

CIHR (2019 - 2024)

“Canadian HIV Cure Enterprise 2.0: Targeting the interplay between myeloid cells and CD4+ T-cells for HIV cure”

Principal Investigators: E.A. Cohen, J.B. Angel, N. Chomont, T.T. Murooka, P. Ancuta, et al.